The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sat., Oct. 1, 11:27 AM

Slide #9. Versartis, Inc. Secondary Offering

Company: Versartis, Inc. (NASDAQ:VSAR)
Date announced: 9/27/2016
Shares Offered: 4,898,000
Date of Pricing: 9/28/2016
Price Per Share: $12.25
Secondary Offering Details: Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that it has commenced an underwritten public offering of shares of its common stock. The company expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. All of the shares in the offering will be sold by Versartis. This offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.-updated 9/28- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced the pricing of an underwritten public offering of 4,898,000 shares of its common stock at a public offering price of $12.25 per share. In addition, Versartis has granted the underwriters a 30-day option to purchase up to 734,700 additional shares of common stock at the public offering price. The offering is expected to close on October 3, 2016, subject to customary closing conditions.

Versartis is an endocrine-focused biopharmaceutical company engaged in developing long-acting form of recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. Somavaratan is a fusion protein consisting of rhGH and a proprietary half-life extension technology known as XTEN™, which Co. in-licensed from Amunix Operating, Inc. GHD is a chronic disease with multiple causes that affects two distinct patient groups, pediatric patients and adult patients, although rhGH treatment options for the two groups are the same.

VSAR SEC Filing Email Alerts Service

Open the VSAR Page at The Online Investor »

Company Name:  Versartis Inc
Website:  www.versartis.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding VSAR:  17
Total Market Value Held by ETFs:  $14.15M
Total Market Capitalization:  $361.00M
% of Market Cap. Held by ETFs:  3.92%
 

Open the VSAR Page at The Online Investor (in a new window) »

October 1, 2016    11:27 AM Eastern
Quotes delayed 20 minutes



Buy (3.00 out of 4)
44th percentile
(ranked lower than approx. 56% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.